We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

129 hedge funds and large institutions have $343M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

37% more call options, than puts

Call options by funds: $5.57M | Put options by funds: $4.08M

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

5% more funds holding

Funds holding: 123129 (+6)

20% less capital invested

Capital invested by funds: $431M → $343M (-$88M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
129
Holders Change
+6
Holders Change %
+4.88%
% of All Funds
3.6%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
31
Increased
51
Reduced
36
Closed
24
Calls
$5.57M
Puts
$4.08M
Net Calls
+$1.5M
Net Calls Change
-$347K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
76
Bridgeway Capital Management
Texas
$327K -$271K -35,000 -36%
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
$327K -$30.8K -3,982 -6%
PCM
78
Palisade Capital Management
New Jersey
$322K +$335K +43,250 +247%
AIG
79
American International Group
New York
$311K -$24.7K -3,194 -5%
DekaBank Deutsche Girozentrale
80
DekaBank Deutsche Girozentrale
Germany
$299K +$73.5K +9,500 +20%
Marshall Wace
81
Marshall Wace
United Kingdom
$288K +$232K +30,032 +124%
LCM
82
Landscape Capital Management
New Jersey
$273K -$35.6K -4,600 -8%
PPA
83
Parametric Portfolio Associates
Washington
$268K -$189K -24,405 -33%
Wells Fargo
84
Wells Fargo
California
$262K -$62.8K -8,121 -14%
SEI Investments
85
SEI Investments
Pennsylvania
$259K +$378K +48,821 New
T. Rowe Price Associates
86
T. Rowe Price Associates
Maryland
$249K
VOYA Investment Management
87
VOYA Investment Management
Georgia
$242K -$85K -10,979 -19%
Tudor Investment Corp
88
Tudor Investment Corp
Connecticut
$225K -$99.9K -12,909 -23%
Balyasny Asset Management
89
Balyasny Asset Management
Illinois
$222K +$174K +22,450 +115%
Royal Bank of Canada
90
Royal Bank of Canada
Ontario, Canada
$190K -$384K -49,555 -58%
State Board of Administration of Florida Retirement System
91
State Board of Administration of Florida Retirement System
Florida
$161K +$8.36K +1,080 +4%
PP
92
Paloma Partners
Connecticut
$158K +$230K +29,740 New
SG Americas Securities
93
SG Americas Securities
New York
$151K +$220K +28,428 New
Bank of America
94
Bank of America
North Carolina
$149K -$17.4K -2,254 -7%
SCM
95
Stevens Capital Management
Pennsylvania
$127K +$186K +23,975 New
Canada Life
96
Canada Life
Manitoba, Canada
$120K
PAM
97
Princeton Alpha Management
New Jersey
$119K +$174K +22,490 New
BG
98
BlackRock Group
United Kingdom
$114K +$38.8K +5,012 +30%
BNP Paribas Financial Markets
99
BNP Paribas Financial Markets
France
$110K +$95.7K +12,364 +149%
PRC
100
Platte River Capital
Colorado
$103K +$150K +19,400 New

SGYP Hedge Fund Activity: Q3 2015 in Review

129 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2015, worth a combined $343M — down 20% from $431M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SGYP positions and 24 closed out — a net gain of 7 holders — while 51 added to existing stakes and 36 trimmed.

The largest buyer was State Street, adding an estimated $25.8M. The largest seller was York Capital Management Global Advisors, exiting entirely with an estimated $15.4M sold.

  • 129 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2015, up from 123 in Q2 2015.
  • Funds reported $343M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2015, down 20% quarter-over-quarter.
  • 31 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2015 and 24 closed out, a net change of +7 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2015 was State Street, an estimated $25.8M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2015 was York Capital Management Global Advisors, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2015.